With COVID-19 infections changing into extra widespread, consultants have lately urged docs to prescribe the antiviral drug Paxlovid greater than they’ve been to attenuate sufferers’ signs and cut back the prospect that they’ll develop extreme illness. The drug is permitted for individuals at increased threat of creating extreme COVID-19, together with those that are older and folks with underlying well being circumstances. However many sufferers who’ve taken Paxlovid have reported creating rebound infections shortly after: testing optimistic once more for the virus after first supposedly clearing the an infection and testing unfavourable. Studies have documented that the repeat optimistic exams are because of the similar virus that precipitated the unique an infection returning once more, fairly than a brand new an infection. In 2022, the U.S. Facilities for Illness Management and Prevention advised physicians in regards to the potential for rebound infections; the company continues to suggest the drug for these at excessive threat of extreme COVID-19 illness, however warned docs to pay attention to rebound since individuals may very well be contagious when their an infection returned.
So-called “Paxlovid rebound” has raised questions on how widespread rebound infections are, each with and with out Paxlovid. Pfizer, Paxlovid’s producer, present in its personal study of the drug that rebound happens in about 1.7% of Paxlovid sufferers, which is barely decrease than what they discovered within the untreated, placebo group. Bigger research haven’t but established how typically rebound happens in people who find themselves contaminated and never handled. However a brand new study published in the Annals of Internal Medicine sheds some gentle on the query, reporting on how possible rebound infections are with out taking an antiviral.
“After I heard stories of individuals telling me they had been getting higher [on Paxlovid] after which bought worse once more, there was all the time a query in my thoughts about whether or not this occurs in the course of the pure COVID-19 an infection restoration interval,” says Dr. Jonathan Li, affiliate professor of medication at Harvard Medical College and Brigham and Ladies’s Hospital and writer of the examine. “Solely by understanding what occurs in untreated infections can we interpret the information we’re getting from sufferers receiving Paxlovid.”
Within the trial—which was half of a bigger community of trials testing varied antiviral therapies for individuals with mild-to-moderate COVID-19—Li tracked the signs and viral ranges, measured by weekly nasal swabs, of about 560 individuals who acquired a placebo over the course of their an infection. Everybody swabbed at first of the examine and at two, three, and 4 weeks later. Additionally they saved a every day log of signs, together with fever, complications, and coughs.
About 26% of those untreated individuals reported that their signs returned round 11 days after their onset, and 31% had increased virus ranges after that they had initially dropped. Total, 3% of individuals reported each a return of signs and the next viral load in the course of the month-long examine interval. (All situations point out an infection rebound.)
“These outcomes inform us that symptom enchancment shouldn’t be a linear course of however, in truth, waxes and wanes over time,” says Li. “It’s additionally very hardly ever related to high-level viral rebound. Even with out Paxlovid…sufferers may have symptom rebound, and probably viral rebound as effectively. We’ve to watch out when saying Paxlovid will trigger a big facet impact of rebound, once we nonetheless simply don’t know.”
Learn Extra: A One-Shot COVID-19 Treatment Shows Promise
Varied research and anecdotal information have discovered vastly completely different charges of rebound amongst each Paxlovid customers and untreated individuals. Anecdotal stories, for example, counsel a a lot increased fee of rebound amongst individuals who take Paxlovid than the Pfizer examine did. However variations between all of this analysis, together with the edge of viral load that the researchers set to report virus ranges, may account for the variations. One benefit of the present examine, says Li, is that the sufferers had been swabbed each week—however the small variety of optimistic rebound samples additionally means it’s laborious to attract any definitive conclusions in regards to the incidence of rebound.
So how ought to the outcomes be interpreted?
Li says it’s most vital to recollect the rationale why individuals take Paxlovid. “The rationale we suggest Paxlovid is to not stop rebound [infections] however to forestall hospitalization and dying,” he says. “After I counsel my sufferers, I inform them that the medical trial [that the U.S. Food and Drug Administration reviewed to authorize Paxlovid] confirmed 90% safety from hospitalization and dying regardless of any viral rebound after remedy. We have to maintain our eyes on the prize.” Scientists are additionally wanting into whether or not Paxlovid may help reduce the risk of Long COVID, although that analysis remains to be early and conclusions can’t but be drawn.
Rebound infections are usually not uncommon with viruses, and researchers are studying extra about why this specific virus bounces again after waning and the way in depth the repeat infections are. One chance, associated to method Paxlovid works, is that the beneficial five days of pills may not be enough to correctly suppress the virus, so it comes again when the treatment stops. One other principle is that in response to the immune system, the virus could also be transferring to completely different components of the physique and discovering new cells to contaminate, inflicting surges in virus ranges and the return of signs. “We want extra intensive information each these taking Paxlovid and people who are usually not, to raised perceive what’s occurring,” says Li.
Deciding who may profit from Paxlovid ought to come after an in depth dialogue between physician and affected person, Li says. “I counsel sufferers relying on their general threat,” he says. “Threat components like age don’t result in dichotomous ‘yes-no’ solutions; it’s a steady spectrum.”
Information from his examine ought to assist in these discussions, to raised stability the dangers and advantages of the remedy for particular person sufferers. Extra research are additionally wanted to make clear the cycle of rebound, since individuals who check optimistic once more after testing unfavourable can nonetheless unfold the virus to others.
Extra Should-Reads From TIME
